Clinical Trial Update: A Study of SLC-0111 and Gemcitabine for Metastatic Pancreatic Ductal Cancer in Subjects Positive for CAIX [Phase 1, Phase 2]

View source ↗

Summary

The Phase 1/2 study of SLC-0111 in combination with gemcitabine for CAIX-positive metastatic pancreatic ductal adenocarcinoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Gemcitabine (Gemcitabine)
• SLC-0111

Snippet

Sponsor: British Columbia Cancer Agency | Conditions: Metastatic Pancreatic Ductal Adenocarcinoma | Phase 1, Phase 2 | Status: TERMINATED